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Abstract
Being protein function a conformation-dependent issue, avoiding aggregation during production is a major
challenge in biotechnological processes, what is often successfully addressed by convenient upstream, midstream
or downstream approaches. Even when obtained in soluble forms, proteins tend to aggregate, especially if stored
and manipulated at high concentrations, as is the case of protein drugs for human therapy. Post-production
protein aggregation is then a major concern in the pharmaceutical industry, as protein stability, pharmacokinetics,
bioavailability, immunogenicity and side effects are largely dependent on the extent of aggregates formation. Apart
from acting at the formulation level, the recombinant nature of protein drugs allows intervening at upstream
stages through protein engineering, to produce analogue protein versions with higher stability and enhanced
therapeutic values.
Aggregation and associated conformational stress of cell
factories (both prokaryotic and eukaryotic) are major
concerns in recombinant protein production, resulting
in low yields, unstable production and limited solubility
and biological activity of the products [1-9]. Basic
research on protein folding and the routine implementa-
tion of several analytical procedures such as circular
dichroism, mass spectrometry and infrared spectroscopy
(mostly incorporated from amyloid research) [4,10-16]
have expanded our understanding of how polypeptide
chains cross-interact and aggregate in vivo. In bacteria,
probably the most studied cell factories, aggregation as
inclusion bodies, a quite common event during produc-
tion of heterologous polypeptides [17,18], is now
observed as a complex physiological event in which cel-
lular agents, including chaperones [6,19,20], proteases
[21-23] and actin-like proteins [24] are coordinately act-
ing [24,25] in the frame of the cell’s protein quality con-
trol machinery [26-28]. Despite aggregation as inclusion
bodies might represent a source of relatively pure pro-
teins for further refolding or extraction [29-33], or
unexpectedly, a new type of nano-microparticulate bio-
materials for biotechnological and biomedical applica-
tions [34-39], the use of recombinant proteins for most
of biotechnological and biomedical applications requires
fully soluble protein versions. A particular issue in
recombinant protein aggregation is the occurrence of
soluble aggregates (less apparent that large aggregates),
that are being progressively recognized in production
processes. These soluble clusters adopt a spectrum of
forms (mainly fibrilar, spherical or amorphous) [40,41]
and might be the in vivo physiological precursors and
structural components of bacterial inclusion bodies
[24,42]. Very different approaches have been explored at
upstream, midstream and downstream levels to mini-
mize aggregation during recombinant protein produc-
tion (Figure 1). Such strategies, eventhough being
mostly a trial-and-error process, often result in signifi-
cant improvements of protein solubility [43-46].
Desirably, soluble versions of recombinant proteins
should keep such soluble status in post-production
stages, that is, during storage and use. This need is spe-
cially acute in the case of proteins intended for thera-
peutic uses [47,48]. Protein drugs are commonly
administered parenterally [49], what makes protein
aggregation in stocks or upon administration a main
concern in the Pharma industry (see for instance, http://
www.eahp.eu/content/download/25193/164355/.../Cov-
erStory20-21.pdf.pd). The high concentration at which
proteins drugs are stored and administered [50] specifi-
cally favors aggregation [51]. In this context, diverse
analytical procedures have been developed and
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specifically adapted to the detection of therapeutic pro-
tein aggregation [52-54]. Importantly, aggregation does
not only render drug inactivation during storage, and
fast clearance, reduction of activity, limited bioavailabil-
ity and proteolytic digestion upon administration, but it
also stimulates undesired immunogenicity [55]. This is a
critical issue in clinics as severe side effects observed
upon prolonged protein administration (as in the case of
insulins, interferons, erythropoietin and growth hor-
mone) are antibody-dependent [56-59].
Chemical modification of proteins and the use of
appropriate excipients (Figure 1) are the most taken
approaches for protein drug stabilization [60-62].
Obviously, emerging concepts in Nanotechnology,
Nanomedicine and in Material Sciences offer new bio-
compatible vehicles for protein encapsulation or
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Figure 1 Tool boxes through which protein solubility can be enhanced at different stages of protein production and postproduction
pipelines. Targets for improvement during in vivo administration are summarized in the red framed box, some of them being modulated by
protein aggregation. Appropriate codon selection [82,83], using weak promoters or low copy number plasmids and protein engineering [84] are
the most common upstream strategies (yellow box). Growth at sub-optimal temperatures [85,86], mild induction of gene expression, co-
production of chaperones [87-89] or protein production in protease-deficient strains [90,91] or in mutants with altered redox properties [92] favor
correct protein folding (orange box). Buffers and purification conditions should be optimized as per protein basis to prevent aggregation [93-97].
Alternatively, soluble protein species can be obtained by refolding inclusion body proteins [30-32] or by extracting functional proteins from
inclusion bodies by mild procedures [29] (green box). Once purified, aggregation during storage or administration of protein drugs can be
inhibited by appropriate excipient formulations or by chemical modification [50,60,62,98] (blue box). Also, the use of delivery systems, either
through protein adsorption onto nanoparticles, nano and micro encapsulation or embedding in biocompatible materials stabilize proteins,
expand their half-life in the body and permit a sustained release, resulting in enhanced bioavailability and reduced toxicity [63,64,99]. Upstream
protein engineering strategies that enhance solubility during production can also affect aggregation and performance of protein drugs upon
administration. Also, by this approach, novel functions that improve pharmacological performance of proteins can be gained without necessarily
enhancing solubility (bottom, green framed box).
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embedding, mainly at the nanoscale, through which the
stability, tissue targeting and bioavailability during drug
delivery are dramatically enhanced [63,64]. Many among
those such nanostructured materials are from bacterial
origin [65].
Being proteins flexible molecules suitable to be re-
designed by genetic methods, upstream protein engi-
neering, one of the main approaches to prevent aggrega-
tion during production (Table 1, up), is also useful to
stabilize protein drugs during use (Table 1, bottom). In
addition, modification of the protein primary sequence
permits a fine tuning of protein features such as oligo-
merization, activity, cell targeting and cell penetration,
that represent additional values in the performance of a
protein drug (Table 1; Figure 1, bottom). In this regard,
protein engineering is revealed as an extremely flexible
approach to enhance the stability of proteins during
production, storage and use, but also to improve their
performance in in vivo uses. Reduction of aggregation is
expected to minimize immunogenicity, increase proteo-
lytic stability, improve bioavailability and limit side-
effects, as aggregation has a pivotal role in all these
issues [55,59,66-69]. In addition, protein modification
can offer added values to protein drugs, by conferring
novel functions that improve pharmacological perfor-
mance without necessarily enhancing solubility (Figure
1, green framed box). These include cell or tissue target-
ing or enhanced cell penetration by the fusion to a cell
receptor ligand or an antibody [70-74], enhancing half-
life and bioavailability by fusion to transferrin [75], albu-
min [76], or albumin-binding peptides [77] and crossing
the brain-blood barrier (BBB) by the incorporation of
cationic peptides [78]. Creating multifunctional proteins
by the appropriate combination of protein domains in a
single polypeptide chain is being especially explored for
the construction of protein-only artificial viruses, in
Table 1 Protein engineering strategies to reduce aggregation or derived effects during either production or
administration, illustrated by representative examples.
Protein engineering strategy Result Protein Reference
Improving protein folding during production
Cys®Ser point mutations Reduced aggregation, enhanced proteolytic
stability
bFGFa [100]
Point mutations in an hydrophobic stretch Reduced aggregation 11 beta-HSD1 [101]
Directed evolution/point mutations Reduced aggregation Cytochrome P450sca-2 [102]
Fusion of SUMO tag Improved refolding Fgf15 [103]
Polycationic amino acid tag fusion Reduced aggregation Candida antarctica
lipase B
[104]
Fusion to polylysines or polyarginines Reduced aggregation BPTI-22 [105]
Fusion to MBP Reduced aggregation Ribonuclease inhibitor [106]
Fusion to GrpE Reduced aggregation hIL-3 [107]
Fusion to NusA Reduced aggregation, enhanced proteolytic
stability
E8R viral protein [108]
Improving protein folding, stability and performance
during administration
Single amino acid substitution Inhibited oligomer formation; enhanced
bioavailability
Insulin Aspart ® [109]
Single amino acid substitution Improved folding INF-b-1b (Betaferon ®) [110]
N-terminal peptide deletion Enhanced stability KGF [111]
Fusion with albumin Extended half-life Albinterferon a-2b [76]
Fusion with transferrin Enhanced gastrointestinal adsorption hGH [75]
Artificial consensus protein sequence Enhanced activity Interferon acon-1
(Infergen ®)
[112]
Fusion of a HIV Tat segment Enhanced solubility p53 [113]
Fusion of a HIV Tat protein and ODD Enhanced stability and activity in hypoxic
tumor cells
Casp-3 [114]
Fusion of a HIV Tat protein and sequence modification Cell penetration and selective activation in HIV-
infected cells
Casp-3 [115]
Ligand incorporation (mainly antibody fragments) Enhanced stability and bioavailbility IL-2 [71]
a Abbreviations are: 11 beta-HSD1, 11 beta-Hydroxysteroid dehydrogenase type 1; aFGF, acidic fibroblast growth factor; bFGF: Fgf15, Fibroblast growth factor 15;
BPTI-22, Bovine pancreatic trypsin inhibitor variant 22; Casp-3, caspase 3; HIV, human immunodeficiency virus; hFGF, Human basic fibroblast growth factor; BSA,
bovine serum albumin; HAS, human serum albumin; hGH, human growth hormone; hIL-3, human interleukin-3; KGF, keratinocyte growth factor; IL, interleukin;
MAGOH, Protein mago nashi homolog; MBP, maltose-binding protein; OOD, oxygen-dependent degradation domain of hypoxia-inducible factor-1alpha; rhDNase,
recombinant human DNAse; SUMO, small ubiquitin-related modifier.
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which the therapeutic nucleic acids are encapsulated by
chimerical protein building blocks [72,79-81]. Further
exploration of protein engineering focused on post-pro-
duction issues is strongly required and it should allow
the emergence of optimized drugs to fulfill their increas-
ing demand.
Conclusions
Stability and solubility of recombinant proteins is a criti-
cal issue at both production and post-production stages.
For a biomedical use of proteins as pharmaceuticals,
high solubility not only supports stability but it also
enhances bioavailability and reduces immunogenicity
and undesired toxic effects. Among other approaches to
stabilize protein drugs, such as chemical modification,
proper formulation and encapsulation, protein engineer-
ing is a very flexible route to improve protein folding
during production and reduce aggregation during sto-
rage and in vivo. Furthermore, the modification of pro-
tein primary sequence permits to confer additional
functional values, such as binding to serum albumin,
binding to cell surface receptors and cell membrane (or
BBB) crossing, thus improving biodistribution, expand-
ing the half-life and enhancing the biological potential
of the drug. The wide spectrum of possibilities of post-
production-addressed protein engineering is probably to
be yet realized.
Acknowledgements
We appreciate the financial support received for the design and microbial
production of recombinant proteins for biomedical applications from FISS
(PS09/00165), MICINN (BFU2010-17450, ACI2009-0919, IT2009-0021, EUI2008-
03610), AGAUR (2009SGR-108), CIBER de Bioingeniería, Biomateriales y
Nanomedicina (CIBER-BBN), Spain, and from the European Science
Foundation, which is also funded by the European Commission, Contract no.
ERAS-CT-2003-980409 of the Sixth Framework Programme (ERANET-IB 08-
007). The authors also appreciate the financial support through the project
“Development of nanomedicines for enzymatic replacement therapy in
Fabry disease” granted by the Fundació Marató TV3.
Author details
1Institute for Biotechnology and Biomedicine, Universitat Autònoma de
Barcelona, Bellaterra, 08193 Barcelona, Spain. 2Department of Genetics and
Microbiology, Universitat Autònoma de Barcelona, Bellaterra, 08193
Barcelona, Spain. 3CIBER de Bioingeniería, Biomateriales y Nanomedicina
(CIBER-BBN), Bellaterra, 08193 Barcelona, Spain.
Competing interests
The authors declare that they have no competing interests.
Received: 25 July 2011 Accepted: 1 August 2011
Published: 1 August 2011
References
1. Gasser B, Saloheimo M, Rinas U, Dragosits M, Rodriguez-Carmona E,
Baumann K, et al: Protein folding and conformational stress in microbial
cells producing recombinant proteins: a host comparative overview.
Microb Cell Fact 2008, 7:11.
2. Ciplys E, Samuel D, Juozapaitis M, Sasnauskas K, Slibinskas R:
Overexpression of human virus surface glycoprotein precursors induces
cytosolic unfolded protein response in Saccharomyces cerevisiae. Microb
Cell Fact 2011, 10:37.
3. Parrilli E, Giuliani M, Marino G, Tutino ML: Influence of production process
design on inclusion bodies protein: the case of an Antarctic
flavohemoglobin. Microb Cell Fact 2010, 9:19.
4. Ami D, Natalello A, Schultz T, Gatti-Lafranconi P, Lotti M, Doglia SM, et al:
Effects of recombinant protein misfolding and aggregation on bacterial
membranes. Biochim Biophys Acta 2009, 1794:263-269.
5. Guillemette T, van Peij NN, Goosen T, Lanthaler K, Robson GD, Van Den
Hondel CA, et al: Genomic analysis of the secretion stress response in
the enzyme-producing cell factory Aspergillus niger. BMC Genomics 2007,
8:158.
6. Martinez-Alonso M, Garcia-Fruitos E, Ferrer-Miralles N, Rinas U, Villaverde A:
Side effects of chaperone gene co-expression in recombinant protein
production. Microb Cell Fact 2010, 9:64.
7. Martinez-Alonso M, Gonzalez-Montalban N, Garcia-Fruitos E, Villaverde A:
Learning about protein solubility from bacterial inclusion bodies. Microb
Cell Fact 2009, 8:4.
8. Dragosits M, Frascotti G, Bernard-Granger L, Vazquez F, Giuliani M,
Baumann K, et al: Influence of growth temperature on the production of
antibody Fab fragments in different microbes: a host comparative
analysis. Biotechnol Prog 2011, 27:38-46.
9. Mattanovich D, Gasser B, Hohenblum H, Sauer M: Stress in recombinant
protein producing yeasts. J Biotechnol 2004, 113:121-135.
10. Carrio M, Gonzalez-Montalban N, Vera A, Villaverde A, Ventura S: Amyloid-
like properties of bacterial inclusion bodies. J Mol Biol 2005,
347:1025-1037.
11. Oberg K, Chrunyk BA, Wetzel R, Fink AL: Nativelike secondary structure in
interleukin-1 beta inclusion bodies by attenuated total reflectance FTIR.
Biochemistry 1994, 33:2628-2634.
12. Doglia SM, Ami D, Natalello A, Gatti-Lafranconi P, Lotti M: Fourier
transform infrared spectroscopy analysis of the conformational quality
of recombinant proteins within inclusion bodies. Biotechnol J 2008,
3:193-201.
13. Gonzalez-Montalban N, Natalello A, Garcia-Fruitos E, Villaverde A, Doglia SM:
In situ protein folding and activation in bacterial inclusion bodies.
Biotechnol Bioeng 2008, 100:797-802.
14. Ami D, Natalello A, Taylor G, Tonon G, Maria DS: Structural analysis of
protein inclusion bodies by Fourier transform infrared
microspectroscopy. Biochim Biophys Acta 2006, 1764:793-799.
15. Ami D, Natalello A, Gatti-Lafranconi P, Lotti M, Doglia SM: Kinetics of
inclusion body formation studied in intact cells by FT-IR spectroscopy.
FEBS Lett 2005, 579:3433-3436.
16. Ami D, Bonecchi L, Cali S, Orsini G, Tonon G, Doglia SM: FT-IR study of
heterologous protein expression in recombinant Escherichia coli strains.
Biochim Biophys Acta 2003, 1624:6-10.
17. Villaverde A, Carrio MM: Protein aggregation in recombinant bacteria:
biological role of inclusion bodies. Biotechnol Lett 2003, 25:1385-1395.
18. Baneyx F, Mujacic M: Recombinant protein folding and misfolding in
Escherichia coli. Nat Biotechnol 2004, 22:1399-1408.
19. Gonzalez-Montalban N, Carrio MM, Cuatrecasas S, Aris A, Villaverde A:
Bacterial inclusion bodies are cytotoxic in vivo in absence of functional
chaperones DnaK or GroEL. J Biotechnol 2005, 118(4):406-412.
20. Carrio MM, Villaverde A: Localization of chaperones DnaK and GroEL in
bacterial inclusion bodies. J Bacteriol 2005, 187:3599-3601.
21. Jurgen B, Breitenstein A, Urlacher V, Buttner K, Lin H, Hecker M, et al:
Quality control of inclusion bodies in Escherichia coli. Microb Cell Fact
2010, 9:41.
22. Vera A, Aris A, Carrio M, Gonzalez-Montalban N, Villaverde A: Lon and ClpP
proteases participate in the physiological disintegration of bacterial
inclusion bodies. J Biotechnol 2005, 119:163-171.
23. Carbonell X, Villaverde A: Protein aggregated into bacterial inclusion
bodies does not result in protection from proteolytic digestion.
Biotechnology Letters 2002, 24:1939-1944.
24. Rokney A, Shagan M, Kessel M, Smith Y, Rosenshine I, Oppenheim AB: E.
coli transports aggregated proteins to the poles by a specific and
energy-dependent process. J Mol Biol 2009, 392:589-601.
25. Garcia-Fruitos E, Martinez-Alonso M, Gonzalez-Montalban N, Valli M,
Mattanovich D, Villaverde A: Divergent Genetic Control of Protein
Solubility and Conformational Quality in Escherichia coli. J Mol Biol 2007,
374:195-205.
Vazquez et al. Microbial Cell Factories 2011, 10:60
http://www.microbialcellfactories.com/content/10/1/60
Page 4 of 6
26. Ventura S, Villaverde A: Protein quality in bacterial inclusion bodies.
Trends Biotechnol 2006, 24:179-185.
27. Tyedmers J, Mogk A, Bukau B: Cellular strategies for controlling protein
aggregation. Nat Rev Mol Cell Biol 2010, 11(11):777-788.
28. Gonzalez-Montalban N, Garcia-Fruitos E, Villaverde A: Recombinant protein
solubility-does more mean better? Nat Biotechnol 2007, 25:718-720.
29. Peternel S, Grdadolnik J, Gaberc-Porekar V, Komel R: Engineering inclusion
bodies for non denaturing extraction of functional proteins. Microb Cell
Fact 2008, 7:34.
30. Jungbauer A, Kaar W: Current status of technical protein refolding. J
Biotechnol 2007, 128:587-596.
31. Singh SM, Panda AK: Solubilization and refolding of bacterial inclusion
body proteins. J Biosci Bioeng 2005, 99:303-310.
32. Vallejo LF, Rinas U: Strategies for the recovery of active proteins through
refolding of bacterial inclusion body proteins. Microb Cell Fact 2004, 3:11.
33. Cabrita LD, Bottomley SP: Protein expression and refolding - A practical
guide to getting the most out of inclusion bodies. Biotechnol Annu Rev
2004, 10:31-50.
34. Garcia-Fruitos E, Villaverde A: Friendly production of bacterial inclusion
bodies. Korean J Chem Eng 2010, 27:385-389.
35. Vazquez E, Villaverde A: Engineering building blocks for self-assembling
protein nanoparticles. Microb Cell Fact 2010, 9:101.
36. Villaverde A: Nanotechnology, bionanotechnology and microbial cell
factories. Microb Cell Fact 2010, 9:53.
37. Rodriguez-Carmona E, Cano-Garrido O, Seras-Franzoso J, Villaverde A,
Garcia-Fruitos E: Isolation of cell-free bacterial inclusion bodies. Microb
Cell Fact 2010, 9:71.
38. Peternel S, Komel R: Isolation of biologically active nanomaterial
(inclusion bodies) from bacterial cells. Microb Cell Fact 2010, 9:66.
39. Garcia-Fruitos E: Inclusion bodies: a new concept. Microb Cell Fact 2010,
9:80.
40. de Marco A, Sevastsyanovich YR, Cole JA: Minimal information for protein
functional evaluation (MIPFE) workshop. N Biotechnol 2009, 25:170.
41. de Marco A: Minimal information: an urgent need to assess the
functional reliability of recombinant proteins used in biological
experiments. Microb Cell Fact 2008, 7:20.
42. Morell M, Bravo R, Espargaro A, Sisquella X, Aviles FX, Fernandez-
Busquets X, et al: Inclusion bodies: specificity in their aggregation
process and amyloid-like structure. Biochim Biophys Acta 2008,
1783:1815-1825.
43. Sorensen HP, Mortensen KK: Soluble expression of recombinant proteins
in the cytoplasm of Escherichia coli. Microb Cell Fact 2005, 4:1.
44. Makino T, Skretas G, Georgiou G: Strain engineering for improved
expression of recombinant proteins in bacteria. Microb Cell Fact 2011,
10:32.
45. Kolaj O, Spada S, Robin S, Wall JG: Use of folding modulators to improve
heterologous protein production in Escherichia coli. Microb Cell Fact
2009, 8:9.
46. Sorensen HP, Mortensen KK: Advanced genetic strategies for recombinant
protein expression in Escherichia coli. J Biotechnol 2005, 115:113-128.
47. Ferrer-Miralles N, Domingo-Espin J, Corchero JL, Vazquez E, Villaverde A:
Microbial factories for recombinant pharmaceuticals. Microb Cell Fact
2009, 8:17.
48. Leader B, Baca QJ, Golan DE: Protein therapeutics: a summary and
pharmacological classification. Nat Rev Drug Discov 2008, 7:21-39.
49. Antosova Z, Mackova M, Kral V, Macek T: Therapeutic application of
peptides and proteins: parenteral forever? Trends Biotechnol 2009,
27:628-635.
50. Shire SJ, Shahrokh Z, Liu J: Challenges in the development of high
protein concentration formulations. J Pharm Sci 2004, 93:1390-1402.
51. Ellis RJ, Minton AP: Protein aggregation in crowded environments. Biol
Chem 2006, 387:485-497.
52. Garcia-Fruitos E, Vazquez E, Gonzalez-Montalban N, Ferrer-Miralles N,
Villaverde A: Analytical Approaches for Assessing Aggregation of Protein
Biopharmaceuticals. Curr Pharm Biotechnol 2011.
53. Bobst CE, Kaltashov IA: Advanced Mass Spectrometry-Based Methods for
the Analysis of Conformational Integrity of Biopharmaceutical Products.
Curr Pharm Biotechnol 2011.
54. Bertucci C, Pistolozzi M, De SA: Structural Characterization of
Recombinant Therapeutic Proteins by Circular Dichroism. Curr Pharm
Biotechnol 2011.
55. Richard J, Prang N: The formulation and immunogenicity of therapeutic
proteins: Product quality as a key factor. IDrugs 2010, 13:550-558.
56. Katagiri D, Shibata M, Katsuki T, Masumoto S, Katsuma A, Minami E, et al:
Antiepoetin antibody-related pure red cell aplasia: successful remission
with cessation of recombinant erythropoietin alone. Clin Exp Nephrol
2010, 14:501-505.
57. Braun A, Kwee L, Labow MA, Alsenz J: Protein aggregates seem to play a
key role among the parameters influencing the antigenicity of
interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res
1997, 14:1472-1478.
58. Frost H: Antibody-mediated side effects of recombinant proteins.
Toxicology 2005, 209:155-160.
59. Fradkin AH, Carpenter JF, Randolph TW: Immunogenicity of aggregates of
recombinant human growth hormone in mouse models. J Pharm Sci
2009, 98:3247-3264.
60. Jorgensen L, Hostrup S, Moeller EH, Grohganz H: Recent trends in
stabilising peptides and proteins in pharmaceutical formulation -
considerations in the choice of excipients. Expert Opin Drug Deliv 2009,
6:1219-1230.
61. Arakawa T, Tsumoto K, Kita Y, Chang B, Ejima D: Biotechnology
applications of amino acids in protein purification and formulations.
Amino Acids 2007, 33:587-605.
62. Frokjaer S, Otzen DE: Protein drug stability: a formulation challenge. Nat
Rev Drug Discov 2005, 4:298-306.
63. Parveen S, Misra R, Sahoo SK: Nanoparticles: a boon to drug delivery,
therapeutics, diagnostics and imaging. Nanomedicine 2011.
64. Singh S: Nanomedicine-nanoscale drugs and delivery systems. J Nanosci
Nanotechnol 2010, 10:7906-7918.
65. Rodriguez-Carmona E, Villaverde A: Nanostructured bacterial materials for
innovative medicines. Trends Microbiol 2010, 18:423-430.
66. Antonelli G: Reflections on the immunogenicity of therapeutic proteins.
Clin Microbiol Infect 2008, 14:731-733.
67. De Groot AS, Scott DW: Immunogenicity of protein therapeutics. Trends
Immunol 2007, 28:482-490.
68. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W:
Antibody response to aggregated human interferon alpha2b in wild-
type and transgenic immune tolerant mice depends on type and level
of aggregation. J Pharm Sci 2006, 95:1084-1096.
69. Schellekens H: Bioequivalence and the immunogenicity of
biopharmaceuticals. Nat Rev Drug Discov 2002, 1:457-462.
70. Pardridge WM: Blood-brain barrier delivery of protein and non-viral gene
therapeutics with molecular Trojan horses. J Control Release 2007,
122(3):345-348.
71. Sondel PM, Hank JA, Gan J, Neal Z, Albertini MR: Preclinical and clinical
development of immunocytokines. Curr Opin Investig Drugs 2003,
4:696-700.
72. Vazquez E, Ferrer-Miralles N, Mangues R, Corchero JL, Schwartz S Jr,
Villaverde A: Modular protein engineering in emerging cancer therapies.
Curr Pharm Des 2009, 15:893-916.
73. Boado RJ, Zhang Y, Zhang Y, Pardridge WM: Genetic engineering,
expression, and activity of a fusion protein of a human neurotrophin
and a molecular Trojan horse for delivery across the human blood-brain
barrier. Biotechnol Bioeng 2007, 97:1376-1386.
74. Dietz GP, Bahr M: Delivery of bioactive molecules into the cell: the Trojan
horse approach. Mol Cell Neurosci 2004, 27:85-131.
75. Amet N, Wang W, Shen WC: Human growth hormone-transferrin fusion
protein for oral delivery in hypophysectomized rats. J Control Release
2010, 141:177-182.
76. Subramanian GM, Fiscella M, Lamouse-Smith A, Zeuzem S, McHutchison JG:
Albinterferon alpha-2b: a genetic fusion protein for the treatment of
chronic hepatitis C. Nat Biotechnol 2007, 25:1411-1419.
77. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D,
et al: Albumin binding as a general strategy for improving the
pharmacokinetics of proteins. J Biol Chem 2002, 277:35035-35043.
78. de Boer AG, Gaillard PJ: Drug targeting to the brain. Annu Rev Pharmacol
Toxicol 2007, 47:323-355.
79. Aris A, Villaverde A: Modular protein engineering for non-viral gene
therapy. Trends Biotechnol 2004, 22:371-377.
80. Vazquez E, Ferrer-Miralles N, Villaverde A: Peptide-assisted traffic
engineering for nonviral gene therapy. Drug Discov Today 2008,
13:1067-1074.
Vazquez et al. Microbial Cell Factories 2011, 10:60
http://www.microbialcellfactories.com/content/10/1/60
Page 5 of 6
81. Ferrer-Miralles N, Vazquez E, Villaverde A: Membrane-active peptides for
non-viral gene therapy: making the safest easier. Trends Biotechnol 2008,
26:267-275.
82. Rosano GL, Ceccarelli EA: Rare codon content affects the solubility of
recombinant proteins in a codon bias-adjusted Escherichia coli strain.
Microb Cell Fact 2009, 8:41.
83. Lee Y, Zhou T, Tartaglia GG, Vendruscolo M, Wilke CO: Translationally
optimal codons associate with aggregation-prone sites in proteins.
Proteomics 2010, 10:4163-4171.
84. Kamionka M: Engineering of therapeutic proteins production in
Escherichia coli. Curr Pharm Biotechnol 2011, 12:268-274.
85. Vera A, Gonzalez-Montalban N, Aris A, Villaverde A: The conformational
quality of insoluble recombinant proteins is enhanced at low growth
temperatures. Biotechnol Bioeng 2007, 96:1101-1106.
86. Strandberg L, Enfors SO: Factors influencing inclusion body formation in
the production of a fused protein in Escherichia coli. Appl Environ
Microbiol 1991, 57:1669-1674.
87. de Marco A, Deuerling E, Mogk A, Tomoyasu T, Bukau B: Chaperone-based
procedure to increase yields of soluble recombinant proteins produced
in E. coli. BMC Biotechnol 2007, 7:32.
88. de Marco A: Protocol for preparing proteins with improved solubility by
co-expressing with molecular chaperones in Escherichia coli. Nat Protoc
2007, 2:2632-2639.
89. de Marco A: Protocol for preparing proteins with improved solubility by
co-expressing with molecular chaperones in Escherichia coli. Nat Protoc
2007, 2:2632-2639.
90. Makrides SC: Strategies for achieving high-level expression of genes in
Escherichia coli. Microbiol Rev 1996, 60:512-538.
91. Gleeson MA, White CE, Meininger DP, Komives EA: Generation of protease-
deficient strains and their use in heterologous protein expression.
Methods Mol Biol 1998, 103:81-94.
92. de Marco A: Strategies for successful recombinant expression of disulfide
bond-dependent proteins in Escherichia coli. Microb Cell Fact 2009, 8:26.
93. Gibson TJ, Mccarty K, Mcfadyen IJ, Cash E, Dalmonte P, Hinds KD, et al:
Application of a high-throughput screening procedure with PEG-
induced precipitation to compare relative protein solubility during
formulation development with IgG1 monoclonal antibodies. J Pharm Sci
2011, 100:1009-1021.
94. Bondos SE, Bicknell A: Detection and prevention of protein aggregation
before, during, and after purification. Anal Biochem 2003, 316:223-231.
95. Golovanov AP, Hautbergue GM, Wilson SA, Lian LY: A simple method for
improving protein solubility and long-term stability. J Am Chem Soc 2004,
126:8933-8939.
96. Ducat T, Declerck N, Gostan T, Kochoyan M, Demene H: Rapid
determination of protein solubility and stability conditions for NMR
studies using incomplete factorial design. J Biomol NMR 2006, 34:137-151.
97. Gosavi RA, Mueser TC, Schall CA: Optimization of buffer solutions for
protein crystallization. Acta Crystallogr D Biol Crystallogr 2008, 64:506-514.
98. Rathore N, Rajan RS: Current perspectives on stability of protein drug
products during formulation, fill and finish operations. Biotechnol Prog
2008, 24:504-514.
99. Tiwari AK, Gajbhiye V, Sharma R, Jain NK: Carrier mediated protein and
peptide stabilization. Drug Deliv 2010, 17:605-616.
100. Rinas U, Tsai LB, Lyons D, Fox GM, Stearns G, Fieschko J, et al: Cysteine to
serine substitutions in basic fibroblast growth factor: effect on inclusion
body formation and proteolytic susceptibility during in vitro refolding.
Biotechnology NY 1992, 10:435-440.
101. Lawson AJ, Walker EA, White SA, Dafforn TR, Stewart PM, Ride JP:
Mutations of key hydrophobic surface residues of 11 beta-
hydroxysteroid dehydrogenase type 1 increase solubility and
monodispersity in a bacterial expression system. Protein Sci 2009,
18:1552-1563.
102. Li P, Guan H, Li J, Lin Z: Heterologous expression, purification, and
characterization of cytochrome P450sca-2 and mutants with improved
solubility in Escherichia coli. Protein Expr Purif 2009, 65:196-203.
103. Kong B, Guo GL: Enhanced In Vitro Refolding of Fibroblast Growth Factor
15 with the Assistance of SUMO Fusion Partner. PLoS One 2011, 6:e20307.
104. Jung HJ, Kim SK, Min WK, Lee SS, Park K, Park YC, et al: Polycationic amino
acid tags enhance soluble expression of Candida antarctica lipase B in
recombinant Escherichia coli. Bioprocess Biosyst Eng 2011.
105. Kato A, Maki K, Ebina T, Kuwajima K, Soda K, Kuroda Y: Mutational analysis
of protein solubility enhancement using short peptide tags. Biopolymers
2007, 85:12-18.
106. Guo W, Cao L, Jia Z, Wu G, Li T, Lu F, et al: High level soluble production
of functional ribonuclease inhibitor in Escherichia coli by fusing it to
soluble partners. Protein Expr Purif 2011, 77:185-192.
107. Davis GD, Elisee C, Newham DM, Harrison RG: New fusion protein systems
designed to give soluble expression in Escherichia coli. Biotechnol Bioeng
1999, 65:382-388.
108. De M, Stier G, Blandin S, de MA: The solubility and stability of
recombinant proteins are increased by their fusion to NusA. Biochem
Biophys Res Commun 2004, 322:766-771.
109. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, et al:
Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin:
absorption kinetics and action profile compared with regular human
insulin in healthy nondiabetic subjects. Diabetes Care 1999, 22:1501-1506.
110. O’Rourke EC, Drummond RJ, Creasey AA: Binding of 125I-labeled
recombinant beta interferon (IFN-beta Ser17) to human cells. Mol Cell
Biol 1984, 4:2745-2749.
111. Hsu E, Osslund T, Nybo R, Chen BL, Kenney WC, Morris CF, et al: Enhanced
stability of recombinant keratinocyte growth factor by mutagenesis.
Protein Eng Des Sel 2006, 19:147-153.
112. Blatt LM, Davis JM, Klein SB, Taylor MW: The biologic activity and
molecular characterization of a novel synthetic interferon-alpha species,
consensus interferon. J Interferon Cytokine Res 1996, 16:489-499.
113. Justesen S, Buus S, Claesson MH, Pedersen AE: Addition of TAT protein
transduction domain and GrpE to human p53 provides soluble fusion
proteins that can be transduced into dendritic cells and elicit p53-
specific T-cell responses in HLA-A*0201 transgenic mice. Immunology
2007, 122:326-334.
114. Harada H, Hiraoka M, Kizaka-Kondoh S: Antitumor effect of TAT-oxygen-
dependent degradation-caspase-3 fusion protein specifically stabilized
and activated in hypoxic tumor cells. Cancer Res 2002, 62:2013-2018.
115. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF: Killing HIV-
infected cells by transduction with an HIV protease-activated caspase-3
protein. Nat Med 1999, 5:29-33.
doi:10.1186/1475-2859-10-60
Cite this article as: Vazquez et al.: Post-production protein stability:
trouble beyond the cell factory. Microbial Cell Factories 2011 10:60.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vazquez et al. Microbial Cell Factories 2011, 10:60
http://www.microbialcellfactories.com/content/10/1/60
Page 6 of 6
